Hims Cuts 2026 Outlook After Q3 Revenue Miss, Pivots to Branded Weight-Loss Drugs
HIMS sits 61% above its 52-week low of $13.74 on elevated volume (4.5× avg).
Summary
Hims posted Q3 revenue of $890.4 million, up 49% year over year but short of estimates, and a $33 million net loss — then cut its 2026 revenue and adjusted EBITDA forecasts. The guidance cut is the part that matters: growth is decelerating faster than the top line suggests, and the margin picture is already ugly after gross margin fell to 57%. Management is repositioning the weight-loss business around FDA-approved branded drugs, adding Eli Lilly's Zepbound and Foundayo after agreeing to offer Novo Nordisk's Ozempic and Wegovy — a retreat from the compounded GLP-1 model that drew FDA and Visa scrutiny earlier this year. The Peptides+ program launches by late November, though the company expects peptide revenue to be immaterial in Q4. Separately, Dr. Andrew Huberman joined the board with a $3.5 million annual advisory agreement disclosed in an 8-K.
At the time of this announcement, HIMS was trading at $22.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.